Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2022  |  Volume : 18  |  Issue : 2  |  Page : 567--575

Significance of vasohibin 1 in cancer patients: A systematic review and meta analysis


Shuai Liu1, Bing Han2, Meili Sun3, Jingnan Wang4, Yuping Sun5, Yunshan Wang6 
1 Department of Breast Disease Diagnosis and Treatment Center, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University; Department of Breast Disease Diagnosis and Treatment Center, Central Hospital Affiliated to Shandong First Medical University, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
2 Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong, China
3 Department of Breast Disease Diagnosis and Treatment Center, Central Hospital Affiliated to Shandong First Medical University, Jinan Central Hospital Affiliated to Shandong First Medical University; Department of Oncology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
4 Department of Radiation Oncology; Department of Thoracic Surgery National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 Clinical Study Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, China
6 Department of Breast Disease Diagnosis and Treatment Center, Central Hospital Affiliated to Shandong First Medical University, Jinan Central Hospital Affiliated to Shandong First Medical University; Medical Research and Laboratory Diagnostic Center, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China

Correspondence Address:
Yunshan Wang
Medical Research and Laboratory Diagnostic Center, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250013, Shandong; Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, Shandong
China
Yuping Sun
Phase I Clinical Study Center, Shandong Cancer Hospital and Institute, Jinan 250117, Shandong
China

This study analyzed the role of vasohibin-1 (VASH1) in human cancer outcomes. Relevant original studies on VASH1 expression in cancers were searched from PubMed, ClinicalKey, and Cochrane Library databases. A meta-analysis was performed to evaluate the role of VASH1 in clinicopathological characteristics and overall survival (OS) of patients with tumors. Statistical analysis was performed using the RevMan v. 5.3 software. Our meta-analysis results showed that patients with high VASH1 expression experienced a significantly poor prognosis with a hazard ratio (HR) of 1.69 (95% confidence interval [CI], 1.16– 2.46, P = 0.006) for OS, and an HR of 2.21 (95% CI, 1.32–3.68, P = 0.003) for progression-free survival. Furthermore, the high expression of VASH1 was significantly relevant to advanced tumor node metastasis stages. Thus, VASH1 is a potential biomarker to predict unfavorable clinical outcomes, serving as a potential tumor treatment target.


How to cite this article:
Liu S, Han B, Sun M, Wang J, Sun Y, Wang Y. Significance of vasohibin 1 in cancer patients: A systematic review and meta analysis.J Can Res Ther 2022;18:567-575


How to cite this URL:
Liu S, Han B, Sun M, Wang J, Sun Y, Wang Y. Significance of vasohibin 1 in cancer patients: A systematic review and meta analysis. J Can Res Ther [serial online] 2022 [cited 2022 Dec 4 ];18:567-575
Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2022;volume=18;issue=2;spage=567;epage=575;aulast=Liu;type=0